Ansa Biotechnologies - About the company
Ansa Biotechnologies is a series A company based in Berkeley (United States), founded in 2017 by , and . It operates as a Provider of DNA synthesis technology using enzymes. Ansa Biotechnologies has raised $82M in funding from investors like Horizons Ventures, Fifty Years and Northpond Ventures. The company has 49 active competitors, including 16 funded and 10 that have exited. Its top competitors include companies like Nuclera Nucleics, Twist Bioscience and DNA Script.
Company Details
Provider of DNA synthesis technology using enzymes. The company offers a chemical method and Next-generation technology for synthesis. Their technology is based on polymerase-nucleotide conjugates that have the ability to extend a DNA molecule by one building block at a time.
- Website
- Social
- Email ID
- @ansabio.com
Key Metrics
Founded Year
2017
Location
Berkeley, United States
Stage
Series A
Total Funding
in 5 rounds
Latest Funding Round
Investors
Ranked
3rd among 49 active competitors
Employee Count
as on Dec 31, 2022
Similar Companies
Legal entities associated with Ansa Biotechnologies
Ansa Biotechnologies is associated with 2 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Dec 31, 1999 | - | 689 | 152 | |
Dec 26, 999 | - | 838 | 725 |
Get your free copy of Ansa Biotechnologies's company profile
Ansa Biotechnologies's funding and investors
Ansa Biotechnologies has raised a total funding of $82M over 5 rounds. Its first funding round was on Dec 2018.
Ansa Biotechnologies has 12 institutional investors including Horizons Ventures, Fifty Years and Northpond Ventures.
Here is the list of recent funding rounds of Ansa Biotechnologies:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Apr 13, 2022 | Undisclosed | Conventional Debt | 6148834 | 8534729 | - |
Apr 11, 2022 | $68M | Series A | 7356445 | 2101993 | |
Jul 09, 2020 | $7.9M | Seed | 7287877 | 5381539 | Horizons Ventures, Mubadala, and |
Access funding benchmarks and valuations. Sign up today!View details of Ansa Biotechnologies's funding rounds and investors
Ansa Biotechnologies's founders and board of directors
The founders of Ansa Biotechnologies are , and . is the CEO of Ansa Biotechnologies.
View details of Ansa Biotechnologies's Founder profiles and Board Members
Ansa Biotechnologies's employee count trend
Ansa Biotechnologies has 253 employees as of Dec 22. The total employee count is 59.1% more than what it was in Dec 21. Here is Ansa Biotechnologies's employee count trend over the years:
Uncover Ansa Biotechnologies's growth story! Sign up today!Ansa Biotechnologies's Competitors and alternates
Top competitors of Ansa Biotechnologies include Nuclera Nucleics, Twist Bioscience and DNA Script. Here is the list of Top 10 competitors of Ansa Biotechnologies, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Nuclera Nucleics 2013, Cambridge (United Kingdom), Series C | Developer of a desktop bioprinter to produce genes and proteins | $164M | Fushia Investments, Patient Square CapitalÌý&²¹³¾±è;Ìý | 66/100 |
2nd |  Twist Bioscience 2013, San Francisco (United States), Public | Developer of a semiconductor-based DNA synthesis platform | $321M | Foresite Capital, Polyvalent CapitalÌý&²¹³¾±è;Ìý | 64/100 |
3rd | Ansa Biotechnologies 2017, Berkeley (United States), Series A | Provider of DNA synthesis technology using enzymes | $82M | Codon Capital, Horizons VenturesÌý&²¹³¾±è;Ìý | 62/100 |
4th | DNA Script 2014, Paris (France), Series C | Developer of benchtop DNA printer for nucleic acid synthesis | $315M | Catalio Capital Management, AgilentÌý&²¹³¾±è;Ìý | 50/100 |
5th |  Sensible Biotechnologies 2021, Wilmington (United States), Seed | Developer of mRNA technology for therapeutics and vaccines | $4.32M | BlueYard, Civilization VenturesÌý&²¹³¾±è;Ìý | 50/100 |
6th |  Nutcracker Therapeutics 2018, Emeryville (United States), Series C | Developer of mRNA therapeutics | $227M | A&E Investments, Arch Venture PartnersÌý&²¹³¾±è;Ìý | 49/100 |
7th | Synple Chem 2016, Zurich (Switzerland), Acquired | Developer of automated chemical synthesizers using reagent capsules | $10.2K | Venture Kick, EIC FundÌý&²¹³¾±è;Ìý | 48/100 |
8th | Developer of a portable molecular analyzer for diagnostic purposes | - | 40/100 | ||
9th | Mesa Biotech 2009, San Diego (United States), Acqui-Hired | Provider of point-of-care molecular diagnostic kits | $26.8M | VIDANT Capital, Phase Two VenturesÌý&²¹³¾±è;Ìý | 40/100 |
10th | _1556249482074.png?height=40&width=40){kind=logo} OriCiro Genomics 2018, Tokyo (Japan), Acquired | Developer of technologies for DNA synthesis and amplification | $10.9M | Unreasonable, Ìý&²¹³¾±è;Ìý | 38/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Ansa Biotechnologies's competitors? Click to see the top ones
Ansa Biotechnologies's Investments and acquisitions
Ansa Biotechnologies has made no investments or acquisitions yet.
Reports related to Ansa Biotechnologies
Here is the latest report on Ansa Biotechnologies's sector:
View
News related to Ansa Biotechnologies
Media has covered Ansa Biotechnologies for a total of 2 events in the last 1 year, 2 of them have been about company updates.
•
Business Wire•Jul 30, 2024•Ansa Biotechnologies
•
Business Wire•May 06, 2024•Ansa Biotechnologies
•
BioSpace•Feb 22, 2024•Ansa Biotechnologies
•
Business Wire•Feb 22, 2024•Ansa Biotechnologies
•
Business Wire•Mar 09, 2023•Ansa Biotechnologies
•
Seeking Alpha•Feb 22, 2023•Ansa Biotechnologies, Bio-Techne, Asuragen, Cleveland Clinic and 2 others
•
Business Wire•Sep 06, 2022•, Ansa Biotechnologies
•
•
Business Wire•Apr 11, 2022•Ansa Biotechnologies, Northpond Ventures, RA Capital Management, Altitude Life Science Ventures and 7 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Ansa Biotechnologies
When was Ansa Biotechnologies founded?
Ansa Biotechnologies was founded in 2017.Where is Ansa Biotechnologies located?
Ansa Biotechnologies is located in Berkeley, United States.Is Ansa Biotechnologies a funded company?
Ansa Biotechnologies is a funded company, its first funding round was on Dec 2018.When was the latest funding round of Ansa Biotechnologies?
Ansa Biotechnologies's latest funding round was on Apr 13, 2022.What is the annual revenue of Ansa Biotechnologies?
Annual revenue of Ansa Biotechnologies is undefined as on undefined.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- OWise - London based, 2012 founded, Unfunded company
- Vikraoceantech - India based, Unfunded company
- Berger Paints - Kolkata based, 1923 founded, Acquired company
- A.paul Software Systems - Delhi based, 2003 founded, Unfunded company
- Virgis - Unfunded company
- brainhealthfresno.com - Unfunded company
